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Case Reports
Original article

Re-implantation of suboptimal prostate seed
implantation: technique with intraoperative
treatment planning
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Abstract
Purpose: Post-implant dosimetry following prostate seed implantation (PSI) occasionally reveals suboptimal dosimetric coverage of the gland. Published reports of re-implantation techniques have focused on earlier-generation techniques, including preplanned approaches and stranded seeds. The purpose of this case report is to describe a customizable
approach to perform corrective re-implantation using loose seeds and intraoperative planning technique.
Material and methods: This case report describes a 63-year-old male with favorable risk prostate adenocarcinoma
receiving PSI. Thirty day post-implant dosimetric evaluation revealed suboptimal coverage of the base of the gland. Using guidance from post-implant CT-images and real-time planning, the patient received a corrective re-implantation with
intraoperative planning.
Results: Post-implant dosimetry after re-implantation procedure with intraoperative planning yielded improved target volume coverage that achieved standard dosimetric criteria.
Conclusions: Re-implantation as a salvage treatment technique after sub-optimal PSI is a valid treatment option performed with intraoperative real-time planning.
J Contemp Brachyther 2012; 4, 3: 176-181
DOI: 10.5114/jcb.2012.30684
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Purpose
Standard treatment guidelines for patients with low-risk
prostate cancer include active surveillance, radical prostatectomy, external beam radiation therapy and brachytherapy (seeds, High-Dose-Rate: HDR) [1]. Over the past
several years, transrectal ultrasound guided (TRUS)
brachytherapy with permanent implantation of seeds (PSI)
has proven to be an effective treatment, especially for those
patients with low risk cancers [2,3]. Freedom from biochemical failure is the criterion most commonly used to
measure the effectiveness of a given implantation procedure,
with failure defined as a rise in PSA of 2 ng/mL above the
post-treatment nadir [4]. As PSI techniques have developed
further, it has become increasingly apparent that treatment
success is closely associated with the dosimetric quality
of the implant [5-7]. A post-implant CT scan allows for evaluation of implant quality using measures such as the D90
(highest dose in Gy that covers 90% of the prostate target
volume) and the V100 (percentage of prostate target volume
encompassed by 100% of the prescription dose). The dose

to surrounding organs, most notably the urethra and rectum, is also measured.
Post-implant dosimetry sometimes reveals that a portion
of the prostate has been under-dosed. Without proper dose
coverage, the patient may be more likely to experience a recurrence [8] and thus further treatment options should be
explored. In this scenario, the patient may choose to undergo
a re-implantation procedure whereby the under-dosed
region of the gland may be targeted with corrective addition of seeds. However, repeat PSI poses its own set of difficulties primarily due to the presence of active seeds placed
in the initial procedure; these seeds cannot be well-visualized on ultrasound [9] and the planning can be complex
and error-prone. While the previously implanted seeds are
visible on a CT scan, the CT is not directly compatible with
the intraoperative planning software [10,11]. As a result,
the two imaging techniques must be implemented together,
so that the treatment plan for the second implant properly accounts for the dose already being received by the patient.
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Prior reports of corrective re-implantation techniques
focused on earlier generation techniques, including preplanned approaches and stranded seeds [10-13]. Although
intraoperative planning is now available and widely used
[14], there are no published reports that describe corrective
re-implantation using intraoperative planning. In the current case report, we describe an approach to perform corrective re-implantation using loose seeds and intraoperative planning.

Material and methods
The patient in this case report is a 63-year-old male with
favorable risk prostate adenocarcinoma. His tumor was
a clinical Stage I, T1cN0M0, prostate cancer with an elevated
PSA of 2.1 ng/mL and Gleason score 6 (3+3) in 2/12 cores.
The patient had an American Urological Association (AUA)
symptom index (SI) score of 1 and little to no erectile function prior to treatment. After being offered all treatment options in a multidisciplinary clinic, the patient decided to undergo PSI.
Approximately 1 month prior to prostate seed implantation, the patient was imaged via pelvic CT to estimate the
volume of the prostate. The images were transferred to
the Variseed® (Varian Medical Systems, Palo Alto, CA) planning system. The prostate was delineated by the radiation
oncologist and the total volume (53.4 mL) was used to estimate the number of radioactive I-125 seeds for the implant.
The patient was brought to the operating room (OR) for
seed implantation under general anesthesia in July 2010.
A Foley catheter was inserted to identify the urethra for treatment planning purposes. The patient was positioned in
the dorsal lithotomy position, the perineum was cleansed
and then a TRUS probe was inserted into the rectum and
positioned to visualize the entire prostate. Transverse images were acquired covering the entire extent of the prostate.
The radiation oncologist contoured the prostate to be used as a target volume and organs at risk (bladder and rectum). A treatment plan was generated using the Variseed®
software with a goal of delivering a minimum of 145 Gy to
the periphery of the prostate gland. The estimated D90 was
approximately 180 Gy. Treatment guidelines include rectal 1cc doses less than prescription dose and maximum ure1
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thral doses less than 150% of the prescription dose. The size
of the prostate gland in the OR was approximately 39 mL.
Sixteen needles and 61 seeds were used to deliver the
desired dose distribution (Figs. 1 and 2). Seed activity of
0.481 mCi was used for the implant. A modified peripheral loading technique was used to deliver adequate dose to
the prostate while minimizing dose to the bladder and urethra. Needles were placed using ultrasound guidance and
ultrasound and fluoroscopic imaging were used during seed
deposition. A marker cable was used to assist with defining the prostate base on fluoroscopy during the PSI procedure. The depth of the marker cable was verified of
the base slice as identified on ultrasound. Both ultrasound
and fluoroscopy were used throughout the procedure to verify position relative to the base of the prostate to aid in seed
deposition.
The patient returned for a post implant imaging study
approximately 30 days after PSI, allowing for edema
of the gland to subside [15]. At this point, the patient reported an AUA SI score of 2, with quality of life score of 2.
The patient was imaged via CT and images were sent to
the treatment planning system for contour delineation and
seed identification. The prostate and rectum were contoured.
Since a Foley catheter was not inserted and the urethra is
not easily identified on CT imaging, a volume called “central prostate” was contoured as a surrogate for estimating
urethral doses. Post-implant dosimetry revealed unacceptably low dose coverage (V100, 71.01%; D90, 92.9 Gy). Review of the images demonstrated that the base was underdosed and comparison to the intraoperative images showed
that the base was underestimated on the intraoperative
images (Figs. 3 and 4).
The option of supplementing dose through a second
implant was discussed with the patient and the patient was
amenable to this plan. The post implant CT images were reimported into the planning system and used as an image
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Fig. 1. Needle and seed locations on BK-Standard template
for initial implant

G

Fig. 2. TRUS image of dosimetry from intra-operative treatment plan. Contours include prostate, urethra and rectum.
Isodose lines show coverage of 100%, 125% and 150% of
145 Gy prescription dose
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Fig. 3. Shows inferior coverage at the base of the prostate
gland following PSI

set for the purpose of pre-planning. Despite the limitation
that CT images have no fixed coordinate system relative to
needle positions used in US imaging and that the slice thickness may vary in magnitude from US slice spacing, the approximate seed locations and quantity of additional seeds
necessary to achieve the desired dose distribution were approximated using the CT image set (Fig. 5). Based on preliminary planning studies performed in the Variseed®
planning system, it was determined that approximately
20 additional seeds would be necessary to compensate for
the initially under-dosed region of the gland.

Results
A hypothetical pre-plan, based on the post-implant CT,
was printed and brought to the OR as a guide for the re-implantation procedure (Fig. 6). The corrective re-implantation procedure was performed approximately two months
after the date of the initial implant. In the OR, the patient
was set-up in the dorsal lithotomy position as described
above. TRUS imaging was used to identify the gland and
capture transverse images to the planning system. The prostate, urethra and rectum were again delineated. Before
a new treatment plan was generated, the previously deposited seeds were loaded as a template from the initial plan
and marked as active seeds. Using the printed pre-plan generated from the post-implant CT as a guide and considering the initial seed locations, a composite plan was generated requiring 20 additional seeds deposited through a total
of 12 needles. For plan evaluation, decay of the previously deposited seeds was not taken into consideration and
the activity per seed on the day of each respective implant,
0.481 mCi, was assigned to all seeds (Fig. 7). The quality
of the implant as judged by dosimetric indicators significantly improved after re-implantation judged by CT post
implant dosimetry following the second implant. The V100

Fig. 4. Mid-sagittal views of intended coveraged indicated
by TRUS (upper) and achieved coverage as indicated by
30-day post-operative CT (lower)

improved from 71.01% to 96.88% and the D90 increased from
92.9 Gy to 173.24 Gy. These results were close to the planned
D90 and V100 values of 182.23 Gy and 99.46%, respectively. After re-implantation, the dose received by the urethra
and rectum remained within the acceptable range. Final
post-implant dosimetry was performed 30 days after
the corrective re-implantation (Fig. 8).

Discussion
Although relatively uncommon in high-volume programs, prostate seed implant (PSI) procedures may result
in sub-optimal dosage identified on post-implant dosimetry, requiring further treatment decisions to be made. The
options for a suboptimal PSI with lower than adequate doses include a wait-and-see approach, supplemental external
beam radiation therapy to the entire prostate target volume
or a corrective re-implantation procedure to an underdosed
region(s) of the prostate. Each approach carries its own risks,
including deleterious treatment-related side effects and possible disease recurrence [16]. After being fully informed of his
options, the patient in this case decided to correct the under-dosed region of the prostate through a second PSI procedure that incorporated intraoperative planning techniques.
As demonstrated by this case, re-implantation may be a preferred course of action in some cases where a specific region
of the prostate can be identified to place additional seeds.
In this case, the base was underestimated in the original PSI,
so the corrective re-implantation delivered supplemental
seeds to the base.
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Fig. 5. Shows use of CT images to calculate approximate location and number of seeds needed for supplemental implant. Approximate positions on pre-implant plan served as a guide for seed locations during intra-operative planning

As previously stated, re-implantation presents obstacles
that do not arise in a typical PSI procedure. Due to limitations inherent to the treatment planning technology, it may
be difficult to ascertain the precise location of existing seeds,
thereby making it more challenging to devise an adequate
treatment plan. The approach used here, which incorporated
both the post-implant CT obtained after the original PSI as
well as intraoperative real-time planning proved to be effective in improving the dosimetric quality of the implant
and ultimately the clinical outcome for the patient. This approach is flexible, customizable and can be performed using standard tools available for intraoperatively-planned
brachytherapy with TRUS images.
Prior studies have described re-implantation primarily using a CT guided pre-planning approach [10,12], but previous
reports did not describe techniques that incorporate intra-

operative planning. For these procedures, a post-implant CT
scan was the primary tool used in creating a treatment plan,
allowing for existing seeds to be visualized and new seeds to
be planned for re-implantation. However, the method does
not afford the same flexibility as the intraoperative method
used in this case. Because the treatment is planned approximately one month before the actual procedure, the pre-planning approach has some important limitations. The main challenge is placing the patient in the exact same position used
during planning; it is often difficult to replicate this position
precisely. Also, there may be changes in prostate volume between planning and procedure, leading to deviations from
intended seed location and dosimetry. Intraoperative planning allows for more flexibility such that needle locations and
seed placement can be adjusted as needed during the procedure and dose distributions may be updated continuously
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Fig. 6. Planned needle and seed locations for second implant considering seed locations from first implant

during the corrective PSI [17-19]. Furthermore, previous studies have shown that intraoperative planning leads to a closer match between OR and post-implant dosimetry [20]. This
paper thus describes re-implantation utilizing a contemporary technique with real-time planning.
It should be noted that supplemental EBRT is another option for re-implantation after an unsatisfactory PSI [21]. In
cases where the prostate target volume is routinely underdosed, supplemental EBRT may be preferable to corrective
re-implantation. In cases where the patient reports severe
urinary morbidity after the first PSI procedure or when
the maximum dose delivered to the urethra approaches or

Fig. 7. Intra-operative plan considering seeds from initial
implant

exceeds the tolerance level, it may be prudent to avoid reimplantation. In a situation such as the case presented in this
study, where the area of underdosage is limited to a defined
region, we recommend that corrective re-implantation using an intraoperative, real-time planning approach be employed to achieve target cumulative doses.

Patient Follow-up
The patient feels well 1.5 years after the procedure and
is no longer on alpha blocker therapy. His follow-up PSA
testing shows that it is decreased to 0.70 ng/mL, from baseline value of 2.0 ng/mL.

Fig. 8. Post implant dosimetry from both initial and salvage PSI
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Conclusions
Re-implantation as a salvage treatment technique after
sub-optimal prostate seed implantation is a valid treatment
option and is made easier by an intra-operative real time
planning technique. The method described in this paper
of using the post implant CT as a pre-implant planning tool
to estimate seed number and locations and intra-operative
planning for real time feedback of current and planned seed
locations is feasible. This technique may be adapted for other cases of sub-optimal dosimetry following PSI. Much caution must be placed on doses to the urethra and rectum following the initial and subsequent implants. Intra-operative
planning allows the user more flexibility in patient positioning, locating previously deposited seeds and real time
dosimetry of supplemental seed deposition.
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